A clinical study to see whether applying Himawan Agad on the skin can help prevent nerve problems like numbness, tingling, and pain caused by Paclitaxel chemotherapy.

Open Labelled Passive Controlled Clinical Evaluation of External Application of Himawan Agad as Prophylaxis in Paclitaxel Chemotherapy-Induced Peripheral Neuropathy (PIPN) - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/100214

Enrollment

Registered

2026-01-02

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G620- Drug-induced polyneuropathy

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients having Paclitaxel as their main chemotherapy drug Patients planned for 12 weeks of paclitaxel chemo cycle Age 18 to 70 years

Exclusion criteria

Exclusion criteria: Patients having Diabetic Neuropathy Patients having Peripheral Neuropathy but with acute systemic adverse effects

Design outcomes

Primary

Measure	Time frame
Significantly reduce incidence and severity of PIPNTimepoint: Day0 Day14 Day28 Day35 Day56 Day70 Day84	—

Secondary

Measure	Time frame
Provide symptomatic relief from burning tingling and numbness in case of development of PIPN Improve nerve conduction and restore neurological functionsTimepoint: Day0 Day14 Day28 Day35 Day56 Day70 Day84	—

Countries

India

Contacts

Public ContactDr Prasad Namewar

Bharati Vidyapeeth Deemed to be University College of Ayurved and Hospital

prasad.namewar@bharatividyapeeth.edu9226269869

Outcome results